BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 24060900)

  • 21. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
    Yan Q; Huang Y; Watkins AJ; Kocialkowski S; Zeng N; Hamoudi RA; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
    Haematologica; 2012 Apr; 97(4):595-8. PubMed ID: 22102703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.
    Chan W; Schaffer TB; Pomerantz JL
    Mol Cell Biol; 2013 Jan; 33(2):429-43. PubMed ID: 23149938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
    Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
    Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
    Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
    Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
    Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
    Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
    Valla K; Flowers CR; Koff JL
    Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
    Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
    Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
    Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
    Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
    Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
    Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
    Koehrer S; Burger JA
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.